Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Agape ATP Corporation Common Stock (ATPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: ATPC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -2.17% | Avg. Invested days 17 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 66.01M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.22 | 52 Weeks Range 0.90 - 5.96 | Updated Date 06/29/2025 |
52 Weeks Range 0.90 - 5.96 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -190.21% | Operating Margin (TTM) -249.24% |
Management Effectiveness
Return on Assets (TTM) -10.73% | Return on Equity (TTM) -18.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 65751053 | Price to Sales(TTM) 51.04 |
Enterprise Value 65751053 | Price to Sales(TTM) 51.04 | ||
Enterprise Value to Revenue 50.85 | Enterprise Value to EBITDA -230.43 | Shares Outstanding 50005400 | Shares Floating 21676333 |
Shares Outstanding 50005400 | Shares Floating 21676333 | ||
Percent Insiders 53.29 | Percent Institutions 0.01 |
Upturn AI SWOT
Agape ATP Corporation Common Stock
Company Overview
History and Background
Agape ATP Corporation (formerly ATP, Inc.) has a history that involves evolving business models, with a significant shift towards biotechnology and therapeutic development. While specific founding dates and early milestones can be complex to pinpoint due to corporate changes and restructurings, the company's focus in recent years has been on its proprietary ATP platform and its applications in treating various diseases.
Core Business Areas
- Therapeutic Development: Agape ATP Corporation is primarily focused on the research, development, and commercialization of novel therapeutic compounds. Their core strategy revolves around leveraging their ATP platform to create treatments for unmet medical needs.
- Biotechnology Research: The company engages in extensive research and development in the biotechnology sector, with a particular emphasis on understanding and manipulating cellular energy pathways to combat diseases.
Leadership and Structure
Information on the specific current leadership team and organizational structure of Agape ATP Corporation can be subject to change and is often best obtained from their latest official filings with the SEC (e.g., 10-K, proxy statements) or their corporate website.
Top Products and Market Share
Key Offerings
- Competitors: Various pharmaceutical and biotechnology companies developing treatments for target disease areas (e.g., cardiovascular, neurological, inflammatory).
- Description: Agape ATP Corporation's core asset is its proprietary adenosine triphosphate (ATP) platform. This platform is designed to deliver ATP directly into cells to restore cellular energy and function, with potential applications in various therapeutic areas. Specific product candidates derived from this platform are in various stages of preclinical and clinical development. Market share data for this platform is not yet established as it is still in the development phase. Key competitors in the broader therapeutic areas it aims to address include pharmaceutical companies developing treatments for cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions. Specific competitors for direct ATP delivery or similar cellular energy restoration mechanisms are not widely defined yet.
- Market Share Data:
- Product Name: Proprietary ATP Platform
Market Dynamics
Industry Overview
Agape ATP Corporation operates within the highly competitive and innovation-driven biotechnology and pharmaceutical industries. These sectors are characterized by significant R&D investment, long development cycles, stringent regulatory processes (FDA approval), and the potential for high returns on successful drug development, alongside substantial risks.
Positioning
Agape ATP Corporation is positioned as an early-stage biotechnology company focused on a novel therapeutic approach centered on cellular energy restoration. Its competitive advantage lies in its proprietary ATP platform, which aims to address a fundamental aspect of cellular dysfunction. However, it faces challenges common to early-stage biotechs, including the need for significant capital, successful clinical trial outcomes, and navigating a complex regulatory and market landscape.
Total Addressable Market (TAM)
The TAM for Agape ATP Corporation is dependent on the specific indications for which its ATP platform-derived therapeutics are eventually approved. The potential markets for cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions are in the hundreds of billions of dollars globally. Agape ATP Corporation is positioned to capture a fraction of these markets if its therapies prove effective and achieve regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary ATP delivery platform with potential for broad therapeutic applications.
- Focus on a fundamental cellular mechanism (energy restoration) that could address root causes of disease.
- Potential for novel treatments for diseases with unmet medical needs.
Weaknesses
- Early-stage company with no approved products on the market.
- Significant reliance on successful clinical trial outcomes.
- High capital requirements for research, development, and regulatory approval.
- Limited operational history and established market presence.
Opportunities
- Development of first-in-class therapies for various diseases.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into new therapeutic areas as platform capabilities are demonstrated.
- Advancements in biotechnology and drug delivery technologies.
Threats
- Failure to achieve positive results in clinical trials.
- Regulatory hurdles and delays in obtaining FDA approval.
- Competition from established pharmaceutical companies with existing therapies.
- Inability to secure sufficient funding for continued development.
- Patent challenges and intellectual property disputes.
Competitors and Market Share
Key Competitors
- There are no direct, widely recognized competitors with an identical ATP delivery platform. Competitors are broadly defined by the therapeutic areas Agape ATP Corporation targets.
Competitive Landscape
Agape ATP Corporation's competitive landscape is defined by the established pharmaceutical and biotechnology companies that are developing treatments for the same diseases it aims to address. Its advantage lies in its novel approach to cellular energy, which, if successful, could offer a differentiated treatment option. However, it faces intense competition from companies with significant financial resources, established distribution channels, and proven track records in drug development and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Agape ATP Corporation has primarily been in terms of its research capabilities, scientific advancements, and the progression of its proprietary platform through preclinical and early clinical stages. Financial growth in terms of revenue and profit is not applicable at this stage.
Future Projections: Future projections for Agape ATP Corporation are highly speculative and depend entirely on the successful clinical development and regulatory approval of its therapeutic candidates. Analyst projections, if available, would focus on potential market penetration and revenue upon commercialization.
Recent Initiatives: Recent initiatives would likely involve the advancement of specific drug candidates into clinical trials, the securing of new funding rounds, potential strategic partnerships, and ongoing research to expand the applications of their ATP platform.
Summary
Agape ATP Corporation is an early-stage biotechnology company with a novel ATP platform. Its strength lies in its innovative approach to cellular energy, offering potential for first-in-class therapies. However, it faces significant weaknesses due to its lack of approved products, high capital needs, and reliance on clinical trial success. The company must capitalize on opportunities for partnerships and navigate threats from regulatory hurdles and established competitors to achieve its growth potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Publicly available financial news and analysis websites
- Industry reports on biotechnology and pharmaceutical markets
Disclaimers:
This analysis is based on publicly available information and may not be exhaustive. Financial data and market share information for early-stage companies can be volatile and subject to change. Investing in biotechnology stocks carries significant risk. This information is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agape ATP Corporation Common Stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-10-05 | Chairman of the Board, Founder, Group CEO, President, COO, Treasurer & Secretary Dr. Kok Choong How | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 16 | Website https://www.atpc.com.my |
Full time employees 16 | Website https://www.atpc.com.my | ||
Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. The company operates through Skin care, health and wellness; and Green energy segments. It offers two series of programs that consist of various services and products under the ATP Zeta Health Program and E.A.T.S. names. The company also provides ionized and high bioavailability nutrients to enhance absorption at the cellular level, energized mineral concentrate, soy protein isolate powder, LIVO5, and solutions for sustainability and energy savings; and promotes environmental stewardship. In addition, it promotes wellness and wellbeing lifestyle through online editorials, programs, events, and campaigns, as well as provides health therapies. Further, the company provides renewable energy products, technical solutions, installations, and maintenance services. Agape ATP Corporation was incorporated in 2016 and is headquartered in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.